Pulmonx Corporation Stock 12‑Month Price Target Raised to $3.7, Implies 87% Upside
Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.
How this was made
The 30-second read
Why it matters
Analyst consensus remains a Buy, with three Buys and two Holds, reinforcing the positive outlook.
Market read
The price‑target upgrade provides a fresh catalyst for a small‑cap stock, offering a potential short‑term trade idea.
What to watch
Potential regulatory or reimbursement hurdles for Pulmonx's products could temper upside.
Background
Pulmonx is a micro‑cap medical device company focused on lung disease treatments.
Market effects
May lift sentiment in the pulmonary medical devices niche.
Limited to US small‑cap investors.
Low
Counterpoint
Target raises for micro‑caps can be premature; price may stall if execution risks materialize.
Key entities
- CompanyPulmonx Corporation
US‑listed medical device firm (ticker PNLX).
